BiotechTube
Pantherna Therapeutics

Pantherna Therapeutics

Halle, Germany· Est.
pantherna-therapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $28.5M

Overview

Pantherna Therapeutics is a private, pre-clinical stage biotech focused on overcoming a key limitation in mRNA therapeutics: delivery beyond the liver. The company's proprietary platform, built on its PTXmRNA™ and PTXΔLNP™ technologies, aims to enable tissue-specific targeting, with an initial lead program targeting pulmonary edema. Leveraging public funding and open to partnerships, Pantherna is positioning itself in the competitive next-generation LNP space to expand the reach of mRNA therapies.

PulmonaryVascular

Technology Platform

Proprietary lipid nanoparticle (LNP) platform consisting of PTXmRNA™ (mRNA design) and PTXΔLNP™ (novel lipid formulations) technologies for organ-specific and cell-selective delivery of mRNA therapeutics.

Funding History

2
Total raised:$28.5M
Series A$25M
Seed$3.5M

Opportunities

The global mRNA therapeutics market is expanding rapidly beyond vaccines, creating a massive demand for targeted delivery technologies that can reach tissues beyond the liver.
Pantherna's focus on lung and vascular targeting addresses high-unmet-need areas like pulmonary edema and ARDS.
Its platform also has potential applications in next-generation cell therapies, such as in vivo CAR-T cell engineering.

Risk Factors

The company faces significant technical risk in demonstrating reliable and specific non-hepatic targeting in humans.
It operates in a highly competitive landscape with well-funded rivals pursuing similar LNP innovations.
Financial reliance on finite public grants necessitates a future transition to private capital or partnerships in a challenging funding environment.

Competitive Landscape

Pantherna competes in the next-generation LNP delivery space against large mRNA leaders (Moderna, BioNTech) and a host of specialized biotechs (e.g., ReCode Therapeutics, Acuitas Therapeutics, Arcturus Therapeutics). Differentiation is based on the specificity of lipid formulations for non-hepatic tissues. Success depends on demonstrating superior targeting efficacy and safety profiles compared to these established and emerging players.

More companies in mRNA Therapeutics →More companies in Germany →